Literature DB >> 2421958

Pharmacodynamics of midodrine, an antihypotensive agent.

P K Zachariah, D C Bloedow, T P Moyer, S G Sheps, A Schirger, R D Fealey.   

Abstract

Midodrine is an orally active adrenergic agonist useful in the treatment of hypotension. We have investigated the pharmacodynamics of its active metabolite after oral midodrine therapy in nine patients with severe orthostatic hypotension. Peak plasma levels of the metabolite were reached in 60 to 90 minutes and ranged from 25 to 56 ng/ml. The mean values for distribution volume, plasma clearance, and t1/2 were 4.0 L/kg, 23 ml/min/kg, and 2.1 hours, respectively. Heart rate increased after 5 to 10 mg doses and the increases were statistically significant (P less than 0.05) at 120 minutes. An apparent increase in blood pressure was not statistically significant. The patients said that they felt better.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2421958     DOI: 10.1038/clpt.1986.101

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Management of neurogenic orthostatic hypotension in patients with autonomic failure.

Authors:  Christoph Schroeder; Jens Jordan; Horacio Kaufmann
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

Review 2.  Midodrine. A review of its therapeutic use in the management of orthostatic hypotension.

Authors:  K J McClellan; L R Wiseman; M I Wilde
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

3.  Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure.

Authors:  Claudia E Ramirez; Luis E Okamoto; Amy C Arnold; Alfredo Gamboa; André Diedrich; Leena Choi; Satish R Raj; David Robertson; Italo Biaggioni; Cyndya A Shibao
Journal:  Hypertension       Date:  2014-09-02       Impact factor: 10.190

4.  Severe Hypertension and Bradycardia Secondary to Midodrine Overdose.

Authors:  L Y Wong; A Wong; T Robertson; K Burns; M Roberts; G K Isbister
Journal:  J Med Toxicol       Date:  2016-07-14

5.  Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges.

Authors:  Jose-Alberto Palma; Horacio Kaufmann
Journal:  Semin Neurol       Date:  2020-09-09       Impact factor: 3.420

6.  Preliminary observations on the use of midodrine hydrochloride in the treatment of refractory neurocardiogenic syncope.

Authors:  B P Grubb; B Karas; D Kosinski; K Boehm
Journal:  J Interv Card Electrophysiol       Date:  1999-07       Impact factor: 1.900

7.  Idiopathic orthostatic hypotension, midodrine, and anaesthesia.

Authors:  P J Osborne; L W Lee
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

8.  Prolonged supine hypertension due to midodrine use in an orthostatic hypotensive child.

Authors:  S Olgar; R E Omeroglu
Journal:  Pediatr Cardiol       Date:  2007-05-25       Impact factor: 1.655

Review 9.  Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders.

Authors:  D McTavish; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

10.  Midodrine overdose in children: a case report and review of treatment for hypertensive emergencies.

Authors:  Meryam Jan; Elizabeth Brothers; Thomas A Nakagawa
Journal:  Transl Pediatr       Date:  2021-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.